Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Serum Ferritin Is an Independent Predictive Marker for Stem Cell Mobilization Efficacy in Patients with Hematologic Malignancy.

Soo-Jeong Kim, MD, Hye Won Lee, MD, Sul Hee Yoon, MD, In-Hae Park, MD, Yuri Kim, MD, Jin Seok Kim, MD,PhD, June-Won Cheong, MD, Yoo-Hong Min, MD,PhD

Blood (2006) 108 (11): 5444.

https://doi.org/10.1182/blood.V108.11.5444.5444

Published: 2006

Journal Articles

A Pilot Study of Alemtuzumab Plus Combination Chemotherapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphomas.

Jin Seok Kim, MD, PhD, Soo-Jeong Kim, MD, Hye Won Lee, MD, Sul Hee Yoon, MD, In-Hae Park, MD, Yuri Kim, MD, June-Won Cheong, MD, Yoo-Hong Min, MD,PhD

Blood (2006) 108 (11): 4717.

https://doi.org/10.1182/blood.V108.11.4717.4717

Published: 2006

Journal Articles

The Role of Alemtuzumab Compared to Antitymocyte Globulin in Non-Myeloablative Stem Cell Transplantation; Especially for the Prevention of GVHD and Immune Recovery.

In Hae Park, MD, June-Won Cheong, MD, Jee Young Lee, MD, Jin Seok Kim, MD, PhD, Hyun Ju Chun, Yuri Kim, MD, Sun Young Park, MD, Jin Koo Lee, PhD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 2739.

https://doi.org/10.1182/blood.V106.11.2739.2739

Published: 2005

Journal Articles

RNA Silencing of Aurora Kinase Genes Sensitizes Human Leukemia Cells to the Ara-C-Induced Cell Death Via Caspase-Independent Pathway.

Yoo-Hong Min, MD, PhD, Jin Koo Lee, PhD, Ju In Eom, In Hae Park, MD, Sun Young Park, MD, Yuri Kim, MD, Jin Seok Kim, MD, PhD, June-Won Cheong, MD

Blood (2005) 106 (11): 2468.

https://doi.org/10.1182/blood.V106.11.2468.2468

Published: 2005

Journal Articles

Protein Kinase CK2 Is Associated with Poor Clinical Outcome and Regulates the Expression of Anti-Apoptotic Proteins and PTEN Phosphorylation in Acute Myeloid Leukemia.

June-Won Cheong, MD, Ju In Eom, Jin Koo Lee, PhD, Sun Young Park, MD, Yuri Kim, MD, In Hae Park, MD, Jin Seok Kim, MD, PhD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 2356.

https://doi.org/10.1182/blood.V106.11.2356.2356

Published: 2005

Journal Articles

Iron Overload as a Potential Predictor for Short Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia.

Sun Young Park, MD, Jin Seok Kim, MD, PhD, Yuri Kim, MD, In Hae Park, MD, Hyun Ju Chun, June-Won Cheong, MD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 5395.

https://doi.org/10.1182/blood.V106.11.5395.5395

Published: 2005

Journal Articles

Attenuated Dose of Idarubicin for the Elderly De Novo Acute Myeloid Leukemia with Normal Karyotype.

June-Won Cheong, MD, Yuri Kim, MD, Sun Young Park, MD, In Hae Park, MD, Jin Seok Kim, MD, PhD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 4608.

https://doi.org/10.1182/blood.V106.11.4608.4608

Published: 2005

Journal Articles

Extended Study for Topotecan, Idarubicin, and Intermediate-Dose Cytarabine Combination Chemotherapy in Patients with Refractory or Relapsed Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Yuri Kim, MD, June-Won Cheong, MD, Jin Seok Kim, MD, PhD, In Hae Park, MD, Sun Young Park, MD, Seung Tae Lee, MD, PhD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 4609.

https://doi.org/10.1182/blood.V106.11.4609.4609

Published: 2005

NARROW

Serum Ferritin Is an Independent Predictive Marker for Stem Cell Mobilization Efficacy in Patients with Hematologic Malignancy.

A Pilot Study of Alemtuzumab Plus Combination Chemotherapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphomas.

The Role of Alemtuzumab Compared to Antitymocyte Globulin in Non-Myeloablative Stem Cell Transplantation; Especially for the Prevention of GVHD and Immune Recovery.

RNA Silencing of Aurora Kinase Genes Sensitizes Human Leukemia Cells to the Ara-C-Induced Cell Death Via Caspase-Independent Pathway.

Protein Kinase CK2 Is Associated with Poor Clinical Outcome and Regulates the Expression of Anti-Apoptotic Proteins and PTEN Phosphorylation in Acute Myeloid Leukemia.

Iron Overload as a Potential Predictor for Short Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia.

Attenuated Dose of Idarubicin for the Elderly De Novo Acute Myeloid Leukemia with Normal Karyotype.

Extended Study for Topotecan, Idarubicin, and Intermediate-Dose Cytarabine Combination Chemotherapy in Patients with Refractory or Relapsed Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only